Actively Recruiting
Comparative Study of SMILE, ICL, and Wavelight Plus Alcon Technologies in Myopia Correction
Led by Beijing Visionly Plus Eye Hospital · Updated on 2025-01-23
1000
Participants Needed
2
Research Sites
49 weeks
Total Duration
On this page
Sponsors
B
Beijing Visionly Plus Eye Hospital
Lead Sponsor
H
High Myopia Control Alliance (HIMALAYA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Myopia is a prevalent refractive error with significant lifestyle impact. While traditional SMILE (Small Incision Lenticule Extraction) and ICL (Implantable Collamer Lens) surgeries are standard options, the advent of the Wavelight Plus Alcon system presents a promising new technique. This trial aims to evaluate the safety, efficacy, and patient satisfaction across these methods.
CONDITIONS
Official Title
Comparative Study of SMILE, ICL, and Wavelight Plus Alcon Technologies in Myopia Correction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18-40 years
- Spherical equivalent of -1.00 to -10.00 D
- Stable refraction for at least 12 months
- Informed consent provided
You will not qualify if you...
- Other ocular pathologies
- Previous refractive surgery
- Pregnancy or nursing
- Autoimmune or connective tissue disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beijing New Vision Eye Hospital
Beijing, China, 100020
Actively Recruiting
2
Beijing Visionly Plus Eye Hospital
Beijing, China, 100027
Actively Recruiting
Research Team
P
Peng ZHOU, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here